Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMPIBJK)

Drug Name
Propafenone Drug Info
Synonyms
Propafenona; Propafenonum; Rythmol; Propafenon Hexal; Propafenon hexal (TN); Propafenona [INN-Spanish]; Propafenone (INN); Propafenone [INN:BAN]; Propafenone-HCl; Propafenonum [INN-Latin]; Rythmol SR (TN); Rytmonorm (TN); 1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone; 1-(2-(2-Hydroxy-3-propylaminopropoxy)phenyl)-3-phenylpropan-1-one; 1-[2-(2-Hydroxy-3-(propylamino)propoxy)phenyl]-3-phenyl-1-propanone hydrochloride; 1-[2-(2-Hydroxy-3-[propylamino]-propoxy)phenyl]-3-phenyl-1-propanone; 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one
Therapeutic ClassAntiarrhythmic Agents
Cross-matching ID
PubChem CID
4932
ChEBI ID
CHEMBL63619
CAS Number
CAS 54063-53-5
TTD Drug ID
D0J2KV
VARIDT Drug ID
DR00634
INTEDE Drug ID
DR1361
ACDINA Drug ID
D00562

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.49 0.00e+0 19/20 (95%) SQLE;DHCR7;LSS;...
DNA replication 2.19 0.00e+0 34/36 (94.44%) PCNA;POLD1;MCM4;...
Progesterone-mediated oocyte maturation 2.16 0.00e+0 75/100 (75%) STK10;PIK3CA;ADCY1;...
Mismatch repair 1.94 1.02e-2 22/23 (95.65%) PCNA;MLH1;POLD1;...
Relaxin signaling pathway 1.86 3.27e-2 114/129 (88.37%) GNAS;PLCB1;TGFB1;...
Biosynthesis of unsaturated fatty acids 1.86 2.95e-2 21/27 (77.78%) SCD;FADS2;HACD1;...
Fanconi anemia pathway 1.83 3.11e-2 36/54 (66.67%) MLH1;FANCI;BRIP1;...
Regulation of lipolysis in adipocytes 1.78 3.92e-2 52/55 (94.55%) FABP4;GNAS;PIK3CA;...
Glutathione metabolism 1.75 4.09e-2 43/57 (75.44%) GPX3;G6PD;GPX4;...
ECM-receptor interaction 1.72 4.63e-2 80/88 (90.91%) CD36;THBS2;SDC4;...
NOD-like receptor signaling pathway -1.66 3.35e-2 145/181 (80.11%) JAK1;DEFB4A;DEFA5;...
Primary immunodeficiency -1.68 2.49e-2 33/38 (86.84%) BTK;ZAP70;IGLL1;...
Malaria -1.68 2.55e-2 44/50 (88%) IL6;ICAM1;SDC2;...
Viral myocarditis -1.68 2.72e-2 53/60 (88.33%) HLA-DRB1;CASP9;SGCD;...
Allograft rejection -1.69 2.75e-2 32/38 (84.21%) HLA-DMB;GZMB;HLA-DOB;...
Retinol metabolism -1.73 2.26e-2 41/68 (60.29%) UGT2B17;UGT2B15;ADH5;...
Graft-versus-host disease -1.74 1.95e-2 32/42 (76.19%) IL1A;IL1B;CD80;...
Nicotinate and nicotinamide metabolism -1.75 1.92e-2 25/35 (71.43%) BST1;NT5C2;AOX1;...
Viral protein interaction with cytokine and cytokine re... -1.78 1.51e-2 84/100 (84%) ACKR3;CCL21;IL20RA;...
Mineral absorption -1.80 1.68e-2 48/60 (80%) SLC26A3;MT1M;MT1G;...
Rheumatoid arthritis -1.82 1.60e-2 78/93 (83.87%) IFNG;ATP6V0E1;ATP6V1B2;...
Transcriptional misregulation in cancer -1.84 1.40e-2 158/192 (82.29%) ITGAM;GADD45G;CEBPB;...
IL-17 signaling pathway -1.84 1.63e-2 84/94 (89.36%) TRAF3IP2;IL6;IKBKE;...
NF-kappa B signaling pathway -1.85 1.96e-2 90/104 (86.54%) PLCG2;LCK;TRAF1;...
Staphylococcus aureus infection -1.91 7.54e-3 72/95 (75.79%) MASP2;HLA-DRB1;KRT16;...
Systemic lupus erythematosus -1.92 5.03e-3 45/135 (33.33%) SNRPD1;IFNG;C1QB;...
Pertussis -1.95 3.77e-3 64/76 (84.21%) C1QB;IL6;C4BPB;...
Complement and coagulation cascades -2.17 0.00e+0 76/85 (89.41%) SERPINB2;C1QB;PROCR;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 15uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 10uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H